Literature DB >> 10365668

Effect of scaffold attachment region on transgene expression in retrovirus vector-transduced primary T cells and macrophages.

J Auten1, M Agarwal, J Chen, R Sutton, I Plavec.   

Abstract

The scaffold attachment region of the human interferon beta gene (IFN-SAR) inserted into a retroviral vector improved transgene expression in human primary CD4+ and CD8+ T cells, and in primary monocytemacrophages. In T cells, expression of the Maloney murine leukemia virus (Mo-MuLV)-based retroviral vectors was high in activated cells but low in resting cells. Addition of the IFN-SAR sequence enhanced vector expression 2- to 10-fold, and the effect was particularly pronounced in resting T cells. In CD33+CD14+CD4+ monocyte-macrophages derived from transduced hematopoietic stem/progenitor cells (HSPCs) in vitro, the IFN-SAR enhanced vector expression three- to sixfold. We have used the IFN-SAR-containing vectors to express the RevM10 gene, a trans-dominant mutant of the human immunodeficiency virus type 1 (HIV-1) rev gene. Compared with a standard retroviral vector, the IFN-SAR-containing vector was significantly (p < 0.01) more potent at inhibiting HIV-1 replication in infected CD4+ peripheral blood lymphocytes. In monocytes, however, addition of the IFN-SAR did not significantly improve antiviral efficacy. To understand better the reason for the strong effect of the SAR on antiviral efficacy in T cells we have studied the expression of HIV, Mo-MuLV, and Mo-MuLV + SAR vectors in resting and activated cells. While the expression of all three vectors was lower in resting compared with activated cells, the kinetics of the decrease in expression were fastest for the Mo-MuLV vector, followed by the HIV vector and then the Mo-MuLV + SAR vector. Thus, higher level expression of the Mo-MuLV + SAR vector relative to wild-type HIV at all stages of T cell activation is the most likely explanation for the strong antiviral efficacy. Overall, this study demonstrates the utility of the IFN-SAR sequence for achieving high-level retroviral vector expression in lymphoid and myeloid hematopoietic cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10365668     DOI: 10.1089/10430349950018058

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  7 in total

1.  Performance of genomic bordering elements at predefined genomic loci.

Authors:  Sandra Goetze; Alexandra Baer; Silke Winkelmann; Kristina Nehlsen; Jost Seibler; Karin Maass; Jürgen Bode
Journal:  Mol Cell Biol       Date:  2005-03       Impact factor: 4.272

2.  Primary human T lymphocytes engineered with a codon-optimized IL-15 gene resist cytokine withdrawal-induced apoptosis and persist long-term in the absence of exogenous cytokine.

Authors:  Cary Hsu; Marybeth S Hughes; Zhili Zheng; Regina B Bray; Steven A Rosenberg; Richard A Morgan
Journal:  J Immunol       Date:  2005-12-01       Impact factor: 5.422

3.  Expression of herpes simplex virus ICP47 and human cytomegalovirus US11 prevents recognition of transgene products by CD8(+) cytotoxic T lymphocytes.

Authors:  C Berger; S Xuereb; D C Johnson; K S Watanabe; H P Kiem; P D Greenberg; S R Riddell
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

4.  Human beta interferon scaffold attachment region inhibits de novo methylation and confers long-term, copy number-dependent expression to a retroviral vector.

Authors:  Q Dang; J Auten; I Plavec
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

5.  Variables affecting in vivo performance of high-capacity adenovirus vectors.

Authors:  Gudrun Schiedner; Sabine Hertel; Marion Johnston; Volker Biermann; Volker Dries; Stefan Kochanek
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

6.  Strategies to insulate lentiviral vector-expressed transgenes.

Authors:  Ali Ramezani; Robert G Hawley
Journal:  Methods Mol Biol       Date:  2010

7.  Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes.

Authors:  Concetta Quintarelli; Juan F Vera; Barbara Savoldo; Greta M P Giordano Attianese; Martin Pule; Aaron E Foster; Helen E Heslop; Cliona M Rooney; Malcolm K Brenner; Gianpietro Dotti
Journal:  Blood       Date:  2007-07-17       Impact factor: 22.113

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.